Loading…

NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus

Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to exam...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2014-01, Vol.31 (1), p.796-796, Article 796
Main Authors: Yan, Hongjiang, Wang, Renben, Jiang, Shumei, Zhu, Kunli, Feng, Rui, Xu, Xiaoqing, Meng, Xiangjiao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553
cites cdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553
container_end_page 796
container_issue 1
container_start_page 796
container_title Medical oncology (Northwood, London, England)
container_volume 31
creator Yan, Hongjiang
Wang, Renben
Jiang, Shumei
Zhu, Kunli
Feng, Rui
Xu, Xiaoqing
Meng, Xiangjiao
description Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively ( P  = 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment ( P  = 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels ( P  = 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS ( P  = 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC.
doi_str_mv 10.1007/s12032-013-0796-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1465861097</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1465861097</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</originalsourceid><addsrcrecordid>eNp1kUtr3DAUhUVJaB7tD-gmCLLpxs3Vy7KXIaRNIDSLttCdkK3rGYWx5Uh2YP595M40hEA2utLVd48OOoR8YfCNAeiLxDgIXgATBei6LOADOWZK1QUT7O9B3gulC1AlHJGTlB4AOFO8_kiOuBSghdTHxP38dU1bO9AxovPtRKc10oRD8pN_8tOWToE67PywnJG2a-xDtM6HzEU7bmnoaOrtZkNbXBYbWz-E3i59TGFc29WcPpHDzm4Sft7XU_Ln-_Xvq5vi7v7H7dXlXdFKUU2FlAqBd7Jz2XPTlKLiupKVc9ZWqpKK8Ua2GsE6yxuoQQnNupqja5SQjVLilHzd6Y4xPM6YJtP7tPiyA4Y5GSZLVZUMap3R8zfoQ5jjkN1lSivgWv8TZDuqjSGliJ0Zo-9t3BoGZonA7CIwOQKzRGAgz5ztleemR_cy8f_PM8B3QMpXwwrjq6ffVX0G0jGQ9A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1475027755</pqid></control><display><type>article</type><title>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</title><source>Springer Link</source><creator>Yan, Hongjiang ; Wang, Renben ; Jiang, Shumei ; Zhu, Kunli ; Feng, Rui ; Xu, Xiaoqing ; Meng, Xiangjiao</creator><creatorcontrib>Yan, Hongjiang ; Wang, Renben ; Jiang, Shumei ; Zhu, Kunli ; Feng, Rui ; Xu, Xiaoqing ; Meng, Xiangjiao</creatorcontrib><description>Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively ( P  = 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment ( P  = 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels ( P  = 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS ( P  = 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-013-0796-0</identifier><identifier>PMID: 24307347</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Aged ; Antigens, Neoplasm - blood ; Biomarkers, Tumor - blood ; Carcinoembryonic Antigen - blood ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Small Cell - radiotherapy ; Chemoradiotherapy - methods ; Cisplatin - administration &amp; dosage ; Endosonography ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - radiotherapy ; Etoposide - administration &amp; dosage ; Female ; Hematology ; Humans ; Internal Medicine ; Keratin-19 - blood ; Lymphatic Metastasis ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Phosphopyruvate Hydratase - blood ; Positron-Emission Tomography ; Predictive Value of Tests ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>Medical oncology (Northwood, London, England), 2014-01, Vol.31 (1), p.796-796, Article 796</ispartof><rights>Springer Science+Business Media New York 2013</rights><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</citedby><cites>FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24307347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><creatorcontrib>Xu, Xiaoqing</creatorcontrib><creatorcontrib>Meng, Xiangjiao</creatorcontrib><title>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively ( P  = 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment ( P  = 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels ( P  = 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS ( P  = 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC.</description><subject>Aged</subject><subject>Antigens, Neoplasm - blood</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Small Cell - radiotherapy</subject><subject>Chemoradiotherapy - methods</subject><subject>Cisplatin - administration &amp; dosage</subject><subject>Endosonography</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - radiotherapy</subject><subject>Etoposide - administration &amp; dosage</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Keratin-19 - blood</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Phosphopyruvate Hydratase - blood</subject><subject>Positron-Emission Tomography</subject><subject>Predictive Value of Tests</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kUtr3DAUhUVJaB7tD-gmCLLpxs3Vy7KXIaRNIDSLttCdkK3rGYWx5Uh2YP595M40hEA2utLVd48OOoR8YfCNAeiLxDgIXgATBei6LOADOWZK1QUT7O9B3gulC1AlHJGTlB4AOFO8_kiOuBSghdTHxP38dU1bO9AxovPtRKc10oRD8pN_8tOWToE67PywnJG2a-xDtM6HzEU7bmnoaOrtZkNbXBYbWz-E3i59TGFc29WcPpHDzm4Sft7XU_Ln-_Xvq5vi7v7H7dXlXdFKUU2FlAqBd7Jz2XPTlKLiupKVc9ZWqpKK8Ua2GsE6yxuoQQnNupqja5SQjVLilHzd6Y4xPM6YJtP7tPiyA4Y5GSZLVZUMap3R8zfoQ5jjkN1lSivgWv8TZDuqjSGliJ0Zo-9t3BoGZonA7CIwOQKzRGAgz5ztleemR_cy8f_PM8B3QMpXwwrjq6ffVX0G0jGQ9A</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Yan, Hongjiang</creator><creator>Wang, Renben</creator><creator>Jiang, Shumei</creator><creator>Zhu, Kunli</creator><creator>Feng, Rui</creator><creator>Xu, Xiaoqing</creator><creator>Meng, Xiangjiao</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140101</creationdate><title>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</title><author>Yan, Hongjiang ; Wang, Renben ; Jiang, Shumei ; Zhu, Kunli ; Feng, Rui ; Xu, Xiaoqing ; Meng, Xiangjiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antigens, Neoplasm - blood</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Small Cell - radiotherapy</topic><topic>Chemoradiotherapy - methods</topic><topic>Cisplatin - administration &amp; dosage</topic><topic>Endosonography</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - radiotherapy</topic><topic>Etoposide - administration &amp; dosage</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Keratin-19 - blood</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Phosphopyruvate Hydratase - blood</topic><topic>Positron-Emission Tomography</topic><topic>Predictive Value of Tests</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Hongjiang</creatorcontrib><creatorcontrib>Wang, Renben</creatorcontrib><creatorcontrib>Jiang, Shumei</creatorcontrib><creatorcontrib>Zhu, Kunli</creatorcontrib><creatorcontrib>Feng, Rui</creatorcontrib><creatorcontrib>Xu, Xiaoqing</creatorcontrib><creatorcontrib>Meng, Xiangjiao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Hongjiang</au><au>Wang, Renben</au><au>Jiang, Shumei</au><au>Zhu, Kunli</au><au>Feng, Rui</au><au>Xu, Xiaoqing</au><au>Meng, Xiangjiao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>31</volume><issue>1</issue><spage>796</spage><epage>796</epage><pages>796-796</pages><artnum>796</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Patients with esophageal small cell carcinoma undergoing definitive chemoradiotherapy (CRT) seem to have disparity in tumor response. The identification of CRT sensitivity-related tumor markers would be helpful for selecting patients most likely to benefit from CRT. The aim of this study was to examine the predictive value of biological markers in small cell carcinoma of the esophagus (SCEC) patients treated with definitive CRT. Pretreatment serum levels of neurone-specific enolase (NSE), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), and carcinoembryonic antigen (CEA) were measured by immunoradiometric assays, while the tumor responses were evaluated according to the World Health Organization response criteria. The relationships between pretreatment expression of NSE, CYFRA21-1, CEA, and the tumor response to CRT were analyzed. The effective rates (complete response + partial response) in NSE high and low groups were 10.80 % (9/82) and 37.98 % (31/82), respectively ( P  = 0.003).The results from statistical analysis indicated that the effectiveness of CRT was significantly associated with the serum levels of NSE before treatment ( P  = 0.002). The overall survival (OS) of the patients with high NSE levels was worse than that of those with low NSE levels ( P  = 0.004). In multivariate analysis, low level of NSE was the most significant independent predictor of good OS ( P  = 0.003). The result showed a promising predictive value of NSE regarding to the sensitivity of tumors to CRT. NSE may be a reliable surrogate marker of CRT efficacy in patients with SCEC.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24307347</pmid><doi>10.1007/s12032-013-0796-0</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1357-0560
ispartof Medical oncology (Northwood, London, England), 2014-01, Vol.31 (1), p.796-796, Article 796
issn 1357-0560
1559-131X
language eng
recordid cdi_proquest_miscellaneous_1465861097
source Springer Link
subjects Aged
Antigens, Neoplasm - blood
Biomarkers, Tumor - blood
Carcinoembryonic Antigen - blood
Carcinoma, Small Cell - drug therapy
Carcinoma, Small Cell - radiotherapy
Chemoradiotherapy - methods
Cisplatin - administration & dosage
Endosonography
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - radiotherapy
Etoposide - administration & dosage
Female
Hematology
Humans
Internal Medicine
Keratin-19 - blood
Lymphatic Metastasis
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Paper
Pathology
Phosphopyruvate Hydratase - blood
Positron-Emission Tomography
Predictive Value of Tests
Tomography, X-Ray Computed
Treatment Outcome
title NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A59%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NSE%20can%20predict%20the%20sensitivity%20to%20definitive%20chemoradiotherapy%20of%20small%20cell%20carcinoma%20of%20esophagus&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Yan,%20Hongjiang&rft.date=2014-01-01&rft.volume=31&rft.issue=1&rft.spage=796&rft.epage=796&rft.pages=796-796&rft.artnum=796&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-013-0796-0&rft_dat=%3Cproquest_cross%3E1465861097%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-445e02f4fd056bb63827848ddaa8584512b4c7e0ada2b0905371f92edb534b553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1475027755&rft_id=info:pmid/24307347&rfr_iscdi=true